The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Circulating Tumor Cell (CTC) Diagnostics-Global Market Insights and Sales Trends 2025
Synopsis
Circulatingtumorcells(CTCs)arecellsthathaveshed intothevasculatureorlymphaticsfrom a primarytumorand arecarried around thebodyintheblood circulation.
The global Circulating Tumor Cell (CTC) Diagnostics market size is expected to reach US$ 20170 million by 2029, growing at a CAGR of 15.1% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cell (CTC) Diagnostics in various end use industries. The expanding demands from the Hospitals and clinics, Pharmaceuticals and biotechnology companies, Academic research institutes and CROs, are propelling Circulating Tumor Cell (CTC) Diagnostics market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell (CTC) Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cell (CTC) Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell (CTC) Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell (CTC) Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell (CTC) Diagnostics covered in this report include ApoCell, Inc.(US), Biocep Ltd. (Israel), Biocept, Inc.(US), Biofluidica MicrotechnologiesLLc(US), Celltraffix Inc.(US), ClearbridgeBiomedics(Singapore), Creatv Microtech, Inc.(US), CynvenioBiosystems, Inc.(US) and EpicBiosciencesInc.(US), etc.
The global Circulating Tumor Cell (CTC) Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
ApoCell, Inc.(US)
Biocep Ltd. (Israel)
Biocept, Inc.(US)
Biofluidica MicrotechnologiesLLc(US)
Celltraffix Inc.(US)
ClearbridgeBiomedics(Singapore)
Creatv Microtech, Inc.(US)
CynvenioBiosystems, Inc.(US)
EpicBiosciencesInc.(US)
FluxionBiosciences, Inc.(US)
Ikonisys, Inc.(US)
IVDiagnostics, Inc.(US)
JanssenDiagnosticsLLc(US)
QIAGEnHannoverGmbH (Germany)
RARECELLsSAs(Italy)
ScreenCell(France)
STEMCELlTechnologies, Inc.(Canada)
Global Circulating Tumor Cell (CTC) Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell (CTC) Diagnostics market, Segment by Type:
CTC Enrichment
CTC Detection
Global Circulating Tumor Cell (CTC) Diagnostics market, by Application
Hospitals and clinics
Pharmaceuticals and biotechnology companies
Academic research institutes
CROs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cell (CTC) Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Circulatingtumorcells(CTCs)arecellsthathaveshed intothevasculatureorlymphaticsfrom a primarytumorand arecarried around thebodyintheblood circulation.
The global Circulating Tumor Cell (CTC) Diagnostics market size is expected to reach US$ 20170 million by 2029, growing at a CAGR of 15.1% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cell (CTC) Diagnostics in various end use industries. The expanding demands from the Hospitals and clinics, Pharmaceuticals and biotechnology companies, Academic research institutes and CROs, are propelling Circulating Tumor Cell (CTC) Diagnostics market. CTC Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CTC Detection segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cell (CTC) Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cell (CTC) Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cell (CTC) Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cell (CTC) Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cell (CTC) Diagnostics covered in this report include ApoCell, Inc.(US), Biocep Ltd. (Israel), Biocept, Inc.(US), Biofluidica MicrotechnologiesLLc(US), Celltraffix Inc.(US), ClearbridgeBiomedics(Singapore), Creatv Microtech, Inc.(US), CynvenioBiosystems, Inc.(US) and EpicBiosciencesInc.(US), etc.
The global Circulating Tumor Cell (CTC) Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
ApoCell, Inc.(US)
Biocep Ltd. (Israel)
Biocept, Inc.(US)
Biofluidica MicrotechnologiesLLc(US)
Celltraffix Inc.(US)
ClearbridgeBiomedics(Singapore)
Creatv Microtech, Inc.(US)
CynvenioBiosystems, Inc.(US)
EpicBiosciencesInc.(US)
FluxionBiosciences, Inc.(US)
Ikonisys, Inc.(US)
IVDiagnostics, Inc.(US)
JanssenDiagnosticsLLc(US)
QIAGEnHannoverGmbH (Germany)
RARECELLsSAs(Italy)
ScreenCell(France)
STEMCELlTechnologies, Inc.(Canada)
Global Circulating Tumor Cell (CTC) Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cell (CTC) Diagnostics market, Segment by Type:
CTC Enrichment
CTC Detection
Global Circulating Tumor Cell (CTC) Diagnostics market, by Application
Hospitals and clinics
Pharmaceuticals and biotechnology companies
Academic research institutes
CROs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cell (CTC) Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Circulating Tumor Cell (CTC) Diagnostics
1.1 Circulating Tumor Cell (CTC) Diagnostics Market Overview
1.1.1 Circulating Tumor Cell (CTC) Diagnostics Product Scope
1.1.2 Circulating Tumor Cell (CTC) Diagnostics Market Status and Outlook
1.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Region (2018-2029)
1.4 Global Circulating Tumor Cell (CTC) Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Circulating Tumor Cell (CTC) Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Circulating Tumor Cell (CTC) Diagnostics Market Size (2018-2029)
1.6.1 North America Circulating Tumor Cell (CTC) Diagnostics Market Size (2018-2029)
1.6.2 Europe Circulating Tumor Cell (CTC) Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Market Size (2018-2029)
1.6.4 Latin America Circulating Tumor Cell (CTC) Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Size (2018-2029)
2 Circulating Tumor Cell (CTC) Diagnostics Market by Type
2.1 Introduction
2.1.1 CTC Enrichment
2.1.2 CTC Detection
2.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Circulating Tumor Cell (CTC) Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Circulating Tumor Cell (CTC) Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Type (2018-2029)
3 Circulating Tumor Cell (CTC) Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and clinics
3.1.2 Pharmaceuticals and biotechnology companies
3.1.3 Academic research institutes
3.1.4 CROs
3.2 Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Circulating Tumor Cell (CTC) Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Circulating Tumor Cell (CTC) Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Circulating Tumor Cell (CTC) Diagnostics Revenue Breakdown by Application (2018-2029)
4 Circulating Tumor Cell (CTC) Diagnostics Competition Analysis by Players
4.1 Global Circulating Tumor Cell (CTC) Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cell (CTC) Diagnostics as of 2022)
4.3 Date of Key Players Enter into Circulating Tumor Cell (CTC) Diagnostics Market
4.4 Global Top Players Circulating Tumor Cell (CTC) Diagnostics Headquarters and Area Served
4.5 Key Players Circulating Tumor Cell (CTC) Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Circulating Tumor Cell (CTC) Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 ApoCell, Inc.(US)
5.1.1 ApoCell, Inc.(US) Profile
5.1.2 ApoCell, Inc.(US) Main Business
5.1.3 ApoCell, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.1.4 ApoCell, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 ApoCell, Inc.(US) Recent Developments
5.2 Biocep Ltd. (Israel)
5.2.1 Biocep Ltd. (Israel) Profile
5.2.2 Biocep Ltd. (Israel) Main Business
5.2.3 Biocep Ltd. (Israel) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.2.4 Biocep Ltd. (Israel) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Biocep Ltd. (Israel) Recent Developments
5.3 Biocept, Inc.(US)
5.3.1 Biocept, Inc.(US) Profile
5.3.2 Biocept, Inc.(US) Main Business
5.3.3 Biocept, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.3.4 Biocept, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Biofluidica MicrotechnologiesLLc(US) Recent Developments
5.4 Biofluidica MicrotechnologiesLLc(US)
5.4.1 Biofluidica MicrotechnologiesLLc(US) Profile
5.4.2 Biofluidica MicrotechnologiesLLc(US) Main Business
5.4.3 Biofluidica MicrotechnologiesLLc(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.4.4 Biofluidica MicrotechnologiesLLc(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Biofluidica MicrotechnologiesLLc(US) Recent Developments
5.5 Celltraffix Inc.(US)
5.5.1 Celltraffix Inc.(US) Profile
5.5.2 Celltraffix Inc.(US) Main Business
5.5.3 Celltraffix Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.5.4 Celltraffix Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Celltraffix Inc.(US) Recent Developments
5.6 ClearbridgeBiomedics(Singapore)
5.6.1 ClearbridgeBiomedics(Singapore) Profile
5.6.2 ClearbridgeBiomedics(Singapore) Main Business
5.6.3 ClearbridgeBiomedics(Singapore) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.6.4 ClearbridgeBiomedics(Singapore) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 ClearbridgeBiomedics(Singapore) Recent Developments
5.7 Creatv Microtech, Inc.(US)
5.7.1 Creatv Microtech, Inc.(US) Profile
5.7.2 Creatv Microtech, Inc.(US) Main Business
5.7.3 Creatv Microtech, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.7.4 Creatv Microtech, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Creatv Microtech, Inc.(US) Recent Developments
5.8 CynvenioBiosystems, Inc.(US)
5.8.1 CynvenioBiosystems, Inc.(US) Profile
5.8.2 CynvenioBiosystems, Inc.(US) Main Business
5.8.3 CynvenioBiosystems, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.8.4 CynvenioBiosystems, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 CynvenioBiosystems, Inc.(US) Recent Developments
5.9 EpicBiosciencesInc.(US)
5.9.1 EpicBiosciencesInc.(US) Profile
5.9.2 EpicBiosciencesInc.(US) Main Business
5.9.3 EpicBiosciencesInc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.9.4 EpicBiosciencesInc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 EpicBiosciencesInc.(US) Recent Developments
5.10 FluxionBiosciences, Inc.(US)
5.10.1 FluxionBiosciences, Inc.(US) Profile
5.10.2 FluxionBiosciences, Inc.(US) Main Business
5.10.3 FluxionBiosciences, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.10.4 FluxionBiosciences, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 FluxionBiosciences, Inc.(US) Recent Developments
5.11 Ikonisys, Inc.(US)
5.11.1 Ikonisys, Inc.(US) Profile
5.11.2 Ikonisys, Inc.(US) Main Business
5.11.3 Ikonisys, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.11.4 Ikonisys, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 Ikonisys, Inc.(US) Recent Developments
5.12 IVDiagnostics, Inc.(US)
5.12.1 IVDiagnostics, Inc.(US) Profile
5.12.2 IVDiagnostics, Inc.(US) Main Business
5.12.3 IVDiagnostics, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.12.4 IVDiagnostics, Inc.(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.12.5 IVDiagnostics, Inc.(US) Recent Developments
5.13 JanssenDiagnosticsLLc(US)
5.13.1 JanssenDiagnosticsLLc(US) Profile
5.13.2 JanssenDiagnosticsLLc(US) Main Business
5.13.3 JanssenDiagnosticsLLc(US) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.13.4 JanssenDiagnosticsLLc(US) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.13.5 JanssenDiagnosticsLLc(US) Recent Developments
5.14 QIAGEnHannoverGmbH (Germany)
5.14.1 QIAGEnHannoverGmbH (Germany) Profile
5.14.2 QIAGEnHannoverGmbH (Germany) Main Business
5.14.3 QIAGEnHannoverGmbH (Germany) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.14.4 QIAGEnHannoverGmbH (Germany) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.14.5 QIAGEnHannoverGmbH (Germany) Recent Developments
5.15 RARECELLsSAs(Italy)
5.15.1 RARECELLsSAs(Italy) Profile
5.15.2 RARECELLsSAs(Italy) Main Business
5.15.3 RARECELLsSAs(Italy) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.15.4 RARECELLsSAs(Italy) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.15.5 RARECELLsSAs(Italy) Recent Developments
5.16 ScreenCell(France)
5.16.1 ScreenCell(France) Profile
5.16.2 ScreenCell(France) Main Business
5.16.3 ScreenCell(France) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.16.4 ScreenCell(France) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.16.5 ScreenCell(France) Recent Developments
5.17 STEMCELlTechnologies, Inc.(Canada)
5.17.1 STEMCELlTechnologies, Inc.(Canada) Profile
5.17.2 STEMCELlTechnologies, Inc.(Canada) Main Business
5.17.3 STEMCELlTechnologies, Inc.(Canada) Circulating Tumor Cell (CTC) Diagnostics Products, Services and Solutions
5.17.4 STEMCELlTechnologies, Inc.(Canada) Circulating Tumor Cell (CTC) Diagnostics Revenue (US$ Million) & (2018-2023)
5.17.5 STEMCELlTechnologies, Inc.(Canada) Recent Developments
6 North America
6.1 North America Circulating Tumor Cell (CTC) Diagnostics Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Circulating Tumor Cell (CTC) Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell (CTC) Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Circulating Tumor Cell (CTC) Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell (CTC) Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Circulating Tumor Cell (CTC) Diagnostics Market Dynamics
11.1 Circulating Tumor Cell (CTC) Diagnostics Industry Trends
11.2 Circulating Tumor Cell (CTC) Diagnostics Market Drivers
11.3 Circulating Tumor Cell (CTC) Diagnostics Market Challenges
11.4 Circulating Tumor Cell (CTC) Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
